Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Anaxagoras who wrote (818)	4/1/1998 9:46:00 PM
From: Jim Roof	Read Replies (1) \| Respond to of 1432

I seem to remember someone posting that ABT said that they planned to ship Hextend by year's end. Maybe the FDA will fast track it just so they can make their numbers look good on the new approval program. Just a thought. Jim

To: Anaxagoras who wrote (818)	4/2/1998 5:29:00 PM
From: CMason	Read Replies (1) \| Respond to of 1432

Care should be exercised in interpreting the changes in PDUFA. My understanding is that FDA is not required to reduce review times at all in 1998, but they need to do 25% of their reviews in 10 months or less in 1999, 50% in 2000, 75% in 2001, and achieve 100% 10 month performance in 2002. If that's correct, it's possible that Hextend will receive an FDA decision in less than 12 months, but there's no requirement on the Agency to achieve this. In my experience, FDA typically takes pretty much the full timespan they're allowed. Also, keep in mind that the clock starts when FDA "accepts" the file, which is typically about a month after they physically receive it. Hope this helps. CMason